• Explore /
  • Poster
  • / Targeting IGF-1/2 with xentuzumab (Xe) plus enzalutamide (En) in metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy (DCt) and abiraterone (Abi): Randomized phase II trial results.

Targeting IGF-1/2 with xentuzumab (Xe) plus enzalutamide (En) in metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy (DCt) and abiraterone (Abi): Randomized phase II trial results.

Abstract Poster

Authors

Syed Hussain

Syed A. Hussain

University of Sheffield, Academic Unit of Oncology, Department of Oncology and Metabolism, Sheffield, United Kingdom

Syed A. Hussain , Pablo Maroto , Miguel Ángel Climent , Diletta Bianchini , Robert Hugh Jones , Chia-Chi Lin , Shian-Shiang Wang , Emma Dean , Kate Crossley , Laura Schlieker , Thomas Bogenrieder , Johann S. De Bono

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT02204072

Citation

J Clin Oncol 37, 2019 (suppl; abstr 5030)

DOI

10.1200/JCO.2019.37.15_suppl.5030

Abstract #

5030

Poster Bd #

142

Abstract Disclosures

Similar Posters

First Author: Johann S. De Bono

First Author: Benedito A. Carneiro

First Author: Daniel Peter Petrylak

First Author: Esmail M. Al-Ezzi